References
1. Akazaki K, Stemmerman GN. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J Natl Cancer Inst 1973. 501137–1144.
2. Thomson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride in the development of prostate cancer. N Engl J Med 2003. 349215–224.
3. Gaynor ML. Isoflavones and the prevention and treatment of prostate disease: is there a role? Cleveland Clin J Med 2003. 70203–204.
4. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS. Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst 1998. 901637–1647.
5. Gann PH, Ma J, Giovannucci E, Willett W, Sacks FM, Hennekens CH, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels:results of the prospective analysis. Cancer Res 1999. 591225–1230.
6. Heber D, Lu QY. Overview of mechanisms of action of lycopene. Exp Biol Med 2002. 227920–923.
7. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, et al. Study of prediagnostic selenium level in toe nails and the risk of advanced prostatic cancer. J Natl Cancer Inst 1998. 901219–1224.
8. Klein EA, Thompson IM, Lippman SM, Goodman Pj, Albanes D, Taylor PR, et al. SELECT: the next prostate cancer prevention trial. J Urol 2001. 1661311–1315.
9. Robert RO, Jacobson DJ, Lieber MM, Jacobson SJ, Girman CJ, Rhodes T. Prostate cancer and non-steroidal anti-inflammatory drugs:a prospective association. J Urol suppl 2001. 165256. 62, abstract.
10. Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D:Regulation of target gene expression. J Cell Biochem 2003. 88363–371.